Answers are grounded in this paper and cite their sources.
Bibliometric analysis maps the evolution of paclitaxel-induced neuropathic pain research from 2000 to 2025, indicating key emerging areas.
BackgroundPaclitaxel-induced peripheral neuropathy (PIPN) significantly impairs the quality of life of cancer survivors. A systematic visualization of global research trends in this domain is currently lacking.ObjectiveThis study aims to delineate the global research landscape, emerging hotspots, and evolutionary trends of PIPN research from 2000 to 2025.MethodsRelevant literature was retrieved from Web of Science Core Collection and Scopus. Bibliometric analyses, including co-occurrence and thematic evolution, were performed using VOSviewer and CiteSpace.ResultsA total of 1,795 eligible publications were analyzed, exhibiting an exponential growth trend (R2 = 0.9675R2 = 0.9675). The United States led with 718 publications and the highest citation impact. Supportive Care in Cancer was the most prolific journal. Research focus has shifted from initial toxicity descriptions to underlying mechanisms (e.g., oxidative stress) and quality of life. Cluster analysis identified emerging interests in “anxiety” and psychosocial comorbidities.ConclusionPIPN research is rapidly expanding, moving from phenomenological observation to mechanistic elucidation and holistic management. Future directions include precision medicine and comprehensive biopsychosocial interventions.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: